Herriot Tabuteau, Axsome CEO (Photo by Owen Hoffmann/Patrick McMullan via Getty Images)
Delaying the inevitable? Axsome says FDA review going beyond PDUFA date
The FDA was supposed to wrap up its review of Axsome’s lead and potential blockbuster drug to treat major depressive disorder on Sunday.
Instead, in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
